University of Notre Dame du Lac’s Sage Therapeutics SAGE Stock Holding History

University of Notre Dame du Lac’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,334	Closed	-$2.6M	–	69
2019 Q1	$2.6M	Sell	16,334 -4,645	-22%	-$673K	0.58%	51
2018 Q4	$2.01M	Buy	20,979 +2,472	+13%	+$283K	0.49%	62
2018 Q3	$2.61M	Buy	18,507 +2,684	+17%	+$414K	0.49%	62
2018 Q2	$2.48M	Sell	15,823 -16,455	-51%	-$2.58M	0.48%	59
2018 Q1	$5.2M	Buy	+32,278	New	+$5.48M	0.97%	44
2017 Q4	–	Sell	-30,144	Closed	-$1.88M	–	81
2017 Q3	$1.88M	Sell	30,144 -4,792	-14%	-$376K	0.52%	70
2017 Q2	$2.78M	Sell	34,936 -3,715	-10%	-$269K	0.82%	57
2017 Q1	$2.75M	Buy	+38,651	New	+$2.26M	0.69%	52

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

University of Notre Dame du Lac's SAGE Position: Q2 2019 in Review

University of Notre Dame du Lac sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 16,334 shares — an estimated $2.6M sold.

University of Notre Dame du Lac first reported a position in SAGE in Q1 2017 and held it in 8 quarters. The position peaked at $5.2M in Q1 2018. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

University of Notre Dame du Lac reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
University of Notre Dame du Lac sold 16,334 Sage Therapeutics shares in Q2 2019, an estimated $2.6M.
University of Notre Dame du Lac first reported a position in Sage Therapeutics in Q1 2017 and held it in 8 quarters.
University of Notre Dame du Lac's Sage Therapeutics position peaked at $5.2M in Q1 2018.
272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on University of Notre Dame du Lac's 13F filing for Q2 2019, filed 14 Aug 2019.